Clinically proven by 7,254 spectral data collected from multi-site clinics
Multi-site clinical studies guarantee the clinical efficacy of Spectra-Scope®. A total of 364 patients were recruited for three different study sites in Newcastle Skin Check (Charlestown, Australia), Eastern Suburb Dermatology (Bondi Junction, Australia), and Skin Cancer & cosmetic clinic (Neural Nay, Australia). 2,088 data from 348 skin cancer cases, and 5,166 spectral data from 861 benign lesions were used to validate its sensitivity and specificity. The first result was 95.4% sensitivity and 84.7% specificity, which is significantly superior to the visual screening performed by trained physicians. The outcome improved after completing an in-depth neural network training for the Spectra-Scope® with additional 6,654 spectral data, resulting in 97.6% sensitivity and 86.2% specificity. These results show that Spectra-Scope is a clinically proven skin cancer diagnostic system, and the resulting data was published in one of the most renowned medical journals and congress.
Real-time, non-invasive, in-vivo skin cancer diagnostics based on laser spectroscopy and machine learning algorithms using aesthetic lasers
Sung Hyun Pyun, Wanki Min, Saleem Loghdey
Speclipse, Inc., Sunnyvale, CA; Integrated Specialist Healthcare, Miranda, NSW, Australia
Clinical Assessment of a real-time, non-invasive, in-vivo skin cancer diagnostic device based on laser spectroscopy and deep learning algorithm using aesthetic lasers
Girish S. Munavalli, Boncheol L. Goo, Chang-Hun Hun, Wanki Min, Sung Hyung Pyun Dermatology, Laser, and Vein Specialist of the Caroolinas, PLLC, Charlotte, NC; Speclipse, Inc. Sunnyvale, CA; Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea